Amendment to License Agreement for Anti-HER2 AntibodiesLicense Agreement • August 28th, 2006 • Immunogen Inc • Pharmaceutical preparations • California
Genentech and ImmunoGen are parties to the following agreements: that certain License Agreement dated as of May 2, 2000, and amendments thereto (the “License Agreement”); that certain Heads of Agreement, dated as of May 2, 2000, as amended (as so amended, the “Heads of Agreement”); that certain Process Development Heads of Agreement, dated as of June 29, 2001, and amendments thereto, including that certain Amendment No.1 dated November 15, 2002 (the “PD Heads of Agreement”); that certain Manufacturing and Supply Agreement dated as of January 11, 2005, and amendments thereto (the “Clinical Supply Agreement”); that certain Development Agreement dated as of June 1, 2004, and amendments thereto (the “Development Agreement”); and the Quality Services Agreement dated as of June 30, 2005 (the “Quality Services Agreement”) (the License Agreement, the Heads of Agreement, the PD Heads of Agreement, the Clinical Supply Agreement, the Development Agreement and the Quality Services Agreement, colle
PROCESS DEVELOPMENT AGREEMENTProcess Development Agreement • August 28th, 2006 • Immunogen Inc • Pharmaceutical preparations • California
THIS PROCESS DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of the 3rd day of May, 2006 (“Effective Date”), by and between Genentech, Inc., a Delaware corporation with an office at 1 DNA Way, South San Francisco, California 94080-4990 (“Genentech”), and ImmunoGen, Inc., a Massachusetts corporation with corporate headquarters at 128 Sidney Street, Cambridge, MA 02139 (“ImmunoGen”). In this Agreement, Genentech and ImmunoGen each may be referred to individually as a “Party” and together as the “Parties.”
